[Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small cell carcinoma of the lung. A clinical study].

55 selected patients with inoperable small cell carcinoma of the lung have been induced in a randomized prospective trial in order to compare the efficacy of ifosfamide monotherapy with the combination of ifosfamid + CCNU. Initially a control group, treated with symptomatic therapy only, was also included but preliminary analysis revealing that results were unfavourable in comparison to those of the chemotherapy group; this treatment arm was omitted. 53 of 55 patients were evaluable.

[Results of a comparative therapy study for inoperable lung cancer].

In a prospective randomized study 78 selected patients with bronchogenic cancer have been included, and five different treatment modalities have been compared (1. Biologic therapy; 2. Vitamin A + Cytoxan; 3.

[Immunological studies and immunotherapeutic possibilities in inoperable bronchogenic carcinoma (author's transl)].

By establishing an immune profile combined with detailed clinical observation an attempt was made to assess the value of various therapeutic measures, especially immunological methods, in the treatment of inoperable bronchogenic carcinoma. The results indicated that in advanced cases specific immunological measures or stimulation of the immune mechanism only play a supportive role. Toxic side-effects or tumour enhancement were absent.

[Dacarbacinum (DTIC) and bronchogenic carcinoma (author's transl)].

A pilot study is reported on the results achieved with the cytostatic agent dacarbacinum (DTIC) on previously untreated, inoperable bronchogenic carcinomas which had been histologically and/or cytologically verified. Altogether there were 16 patients, i.e.